Live Breaking News & Updates on Enoxaparin Sodium Injection

Share this article
WESTON, Fla., Feb. 2, 2021 /PRNewswire/ -
 Apotex Corp is voluntarily recalling two (2) batches of Enoxaparin Sodium Injection, USP to consumer level due to a packaging error resulting in some syringes barrels containing 150 mg/mL markings (corresponding to 120 mg/0.8mL strength) instead of 100 mg/mL markings (corresponding to 100 mg/mL strength) on the syringe barrel and vice versa. The packaging error was discovered during a customer complaint investigation. To date, Apotex has not received any reports of adverse events related to use of these two batches. The affected product is manufactured by Gland Pharma Limited, Hyderabad, India.
Carton 100mg/mL (CNW Group/Apotex Corp.) ....

United States , Inmar Rx Solutions , Apotex Corp , Drug Administration , Enoxaparin Sodium , Acute Deep Vein Thrombosis , Segment Elevation Myocardial , Enoxaparin Sodium Injection , Sodium Injection , Warehousing Chains , Fedex Standard Overnight , Recall Stock Response Form , Watch Adverse Event Reporting , ஒன்றுபட்டது மாநிலங்களில் , எடுப்போசை ஆழமான நரம்பு த்ரோம்போசிஸ் , பிரிவு உயரம் மாரடைப்பு , சோடியம் ஊசி , கிடங்கு சங்கிலிகள் , ஃபெடெக்ஸ் தரநிலை ஓவர்‌நைட் , ரீகால் ஸ்டாக் பதில் வடிவம் ,